Home Federal Bank of Tennessee reduced its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 2.0% in the third quarter, Holdings Channel reports. The firm owned 13,017 shares of the company’s stock after selling 262 shares during the quarter. Eli Lilly and Company accounts for 3.3% of Home Federal Bank of Tennessee’s holdings, making the stock its 3rd biggest holding. Home Federal Bank of Tennessee’s holdings in Eli Lilly and Company were worth $11,532,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Lynx Investment Advisory bought a new stake in Eli Lilly and Company during the 2nd quarter valued at about $32,000. LGT Financial Advisors LLC bought a new stake in Eli Lilly and Company during the 2nd quarter valued at about $36,000. Redmont Wealth Advisors LLC bought a new stake in Eli Lilly and Company during the 1st quarter valued at about $40,000. Morton Brown Family Wealth LLC increased its stake in Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after purchasing an additional 15 shares in the last quarter. Finally, Cedar Mountain Advisors LLC increased its stake in Eli Lilly and Company by 53.3% during the 3rd quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after purchasing an additional 16 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.
Eli Lilly and Company Price Performance
Shares of NYSE:LLY opened at $909.15 on Wednesday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53. The company has a market capitalization of $864.06 billion, a P/E ratio of 133.90, a P/E/G ratio of 2.79 and a beta of 0.42. The firm’s 50 day simple moving average is $921.67 and its two-hundred day simple moving average is $860.45.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on the stock. BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Guggenheim lifted their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,002.24.
Check Out Our Latest Analysis on Eli Lilly and Company
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- Utilities Stocks Explained – How and Why to Invest in Utilities
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Investing in Construction Stocks
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.